Table 1. The demographic and laboratory parameters of patients with FMF and controls [number (%)].
| Patient group | Control group | p | |
|---|---|---|---|
| Sex (male/female)β | 10/17 (37% / 63%) | 10/17 (37% / 63%) | |
| Age (year) β | 36.2 (±13.3) | 36.78 (±8.89) | |
| BMI (kg/cm2) β | 26.4 (±4.8) | 25.2 (±4.0) | |
| Smokers | 4 (14.8%) | 3 (11.1%) | |
| ESR (mm/h)¥ | 16.7 (2–65) | 15.2 (2–33) | |
| CRP (mg/L) ¥ | 0.3 (0–1.6) | 0.3 (0–0.8) | |
| Osteocalsin (ng/mL) ¥ | 24.5 (3.0–53.4) | 21.9 (11–36.6) | |
| 25-OH vitamin D (ng/mL) ¥ | 14.7 (4.2–34.7) | 39.0 (16–110) | α |
| Serum amiloid (mg/dL) ¥ | 0.9 (0.1–10.1) | 0.4 (0.1–0.6) | |
| Rheumotoid factor (IU/mL) ¥ | 9.8 (3–46) | 7.7 (4–12) | |
| Deoxypyridinoline (ug g/Krea) ¥ | 50.3 (16.3–314) | 33.6 (14–48.3) | |
| Urea (mg/dl) | 22.3 (10–42) | 15.7 (8–31) | |
| Creatine (mg/dl) | 1.2 (0.8–1.9) | 0.9 (0.7–1.3) | |
| ALP (U/l) | 92.7 (52–162) | 82.1 (45–145) |
BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive protein; α p < 0.05 is significant, β the data expressed as mean (±SD), ¥ the data expressed as median (minimum–maximum).